ClinicalTrials.gg
TerminatedNCT00263042CRESCENDOUpdated May 20, 2016

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

A Phase 3 interventional study of Rimonabant and Placebo (for Rimonabant) in Cardiovascular Disease, sponsored by Sanofi. Terminated at 43 sites in 43 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2016-05-20.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision taken in light of demands by certain national health authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18,695
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.

The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV hospitalization in these patients.

Read the detailed description

The estimated study duration per patient is 36 to 53 months. All patients will be followed from randomization until a common study end date, which will occur when the last patient has been followed for 33 months.

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Myocardial infarction
  • cerebrovascular accident
  • obesity
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 18,695 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Waist circumference >102 cm (40 inches) males, >88 cm (35 inches) females, with one coronary heart disease (CHD) equivalent or two major risk factors for cardiovascular disease.

  • CHD equivalents:

    • Recent (within 3 years)documented heart attack
    • Documented symptomatic coronary artery disease
    • Recent (within 3 years) ischemic cerebrovascular episode (stroke or )
    • Documented symptomatic peripheral arterial disease
  • Major risk factors:

    • Documented type 2 diabetes mellitus
    • Metabolic syndrome (NCEP criteria)
    • Asymptomatic cerebrovascular, renal, or peripheral arterial disease, or past abdominal aortic aneurysm repair
    • Elevated high-sensitivity C-reactive protein
    • Age > or = 65 years for males, age > or = 70 years for females

Exclusion criteria

Exclusion Criteria:

  • Obesity of known endocrine origin
  • Pregnant or breastfeeding women
  • Very low calorie diet or weight loss surgery within past 6 months
  • Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation, including uncontrolled serious psychiatric illness
  • Likely cardiovascular intervention within next 1 month
  • Allergy to rimonabant or , or prior participation in a rimonabant trial
  • Receipt of product within past 30 days
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18,695 participants (actual)

Study arms

  • Experimental
    Rimonabant

    Rimonabant 20 mg once daily

    Drug: Rimonabant

  • Placebo comparator
    Placebo

    Placebo (for Rimonabant) once daily.

    Drug: Placebo (for Rimonabant)

Interventions

  • Tablet, oral administration

    Also known as: SR141716, Acomplia

  • DrugPlacebo (for Rimonabant)

    Tablet, oral administration

06

What researchers measure

Primary outcomes

  1. First occurrence of any of myocardial infarction, stroke or cardiovascular (CV) death

    Time frame: From randomization up to common study end date (33-50 months)

Secondary outcomes

  1. First occurrence of any of myocardial infarction, stroke, CV death, and CV hospitalization

    Time frame: From randomization up to common study end date (33-50 months)

  2. All-cause mortality

    Time frame: From randomization up to common study end date (33-50 months)

07

Study locations

43 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • sanofi-aventis Australia & New Zealand administrative office
    Macquarie Park, New South Wales, Australia
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Laval, Quebec, Canada
  • Sanofi-Aventis Administrative Office
    Santiago de Chile, Chile
  • Sanofi-Aventis Administrative Office
    Shangaï, China
  • Sanofi-Aventis Administrative Office
    Santafe de Bogota, Colombia
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Horsholm, Denmark
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Athens, Greece
  • Sanofi-Aventis Administrative Office
    Hong-Kong, Hong Kong
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Dublin, Ireland
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Milano, Italy
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    Mexico, Mexico
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Lysaker, Norway
  • Sanofi-Aventis Administrative Office
    Lima, Peru
  • Sanofi-Aventis Administrative Office
    Makati City, Philippines
  • Sanofi-Aventis Administrative Office
    Warszawa, Poland
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Bucuresti, Romania
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Singapore, Singapore
  • Sanofi-Aventis Administrative Office
    Midrand, South Africa
  • Sanofi-Aventis Administrative Office
    Madrid, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Geneva, Switzerland
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administrative Office
    Bangkok, Thailand
  • Sanofi-Aventis Administrative Office
    Megrine, Tunisia
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
  • Sanofi-Aventis Administrative Office
    Guildford, United Kingdom
08

References and documents

Publications

  • Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X. PubMed 20709233 ↗
  • Bhatia G, Bansal V, Harismendy O, Schork NJ, Topol EJ, Frazer K, Bafna V. A covering method for detecting genetic associations between rare variants and common phenotypes. PLoS Comput Biol. 2010 Oct 14;6(10):e1000954. doi: 10.1371/journal.pcbi.1000954. PubMed 20976246 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2005
First posted
Dec 7, 2005
Start
Dec 2005
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results delay requested
Apr 21, 2016
Last update
May 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00263042
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 7, 2005
Start date
Dec 2005
Primary completion
Apr 2009
Completion
Apr 2009
Last update
May 20, 2016

Study contacts

Eric Topol, MD
study chair · Scripps Clinic
Deepak L. Bhatt, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion